Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)

György Bodoky; Max E. Scheulen; Fernando Rivera; Jacek Jassem; Alfredo Carrato; Vladimir Moiseyenko; Ihor Vynnychenko; Jana Prausová; Jean-Luc Van Laethem; Stefano Cascinu; Jaffer A. Ajani

首页> 外文期刊>Journal of Gastrointestinal Cancer >Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)

【24h】

Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)

机译：用顺铂/ S-1和顺铂/ 5-FU治疗的患者的临床获益和健康相关的生活质量评估：一线晚期胃癌研究（FLAGS）的次级终点结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose Patient-reported outcomes (PRO) of health-related quality of life (HRQoL) and time to worsening of clinical benefit parameters were evaluated as secondary end points in the phase 3 first-line advanced gastric cancer study (FLAGS) trial of cisplatin/S-1 versus cisplatin/5-fluorouracil (5-FU) in patients with previously untreated advanced gastric cancer.

机译：目的将患者报告的健康相关生活质量（HRQoL）的结局（PRO）和临床获益参数恶化的时间作为顺铂/三期一线晚期胃癌研究（FLAGS）试验的次要终点先前未经治疗的晚期胃癌患者的S-1与顺铂/ 5-氟尿嘧啶（5-FU）的比较。

著录项

来源
《Journal of Gastrointestinal Cancer》 |2015年第2期|109-117|共9页
作者
György Bodoky; Max E. Scheulen; Fernando Rivera; Jacek Jassem; Alfredo Carrato; Vladimir Moiseyenko; Ihor Vynnychenko; Jana Prausová; Jean-Luc Van Laethem; Stefano Cascinu; Jaffer A. Ajani;
展开▼
作者单位

Department of Oncology">(1);

Department of Medical Oncology West German Cancer Center University Hospital Essen University Duisburg-Essen">(2);

Hospital Universitario Marqués de Valdecilla Medical Oncology Service">(3);

Department of Oncology and Radiotherapy Medical University of Gdansk">(4);

Hospital Universitario Ramon y Cajal Medical Oncology Service">(5);

Federal State Institution N.N. Petrov Research Institute of Oncology at Federal Agency of High Technical Medical Care">(6);

Thoracic Department Regional Oncology Centre Sumy State University">(7);

Motol University Hospital">(8);

Gastroenterology Department Erasmus University Hospital">(9);

Clinica di Oncologia Medica Univertistà Politecnica delle Marche Azienda Ospedaliero-Universitaria">(10);

The University of Texas M.D. Anderson Cancer Center">(11);

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Advanced gastric cancer; Cisplatin; Patient-reported outcomes; Quality of life; S-1; FLAGS trial;

机译：晚期胃癌;顺铂;患者报告的结果;生活质量;S-1;FLAGS试用;

相似文献

外文文献
中文文献

1. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). [J] . Gy?rgy Bodoky, Max E Scheulen, Fernando Rivera, Journal of gastrointestinal cancer. . 2015,第2期

机译：用顺铂/ S-1和顺铂/ 5-FU治疗的患者的临床获益和健康相关的生活质量评估：一线晚期胃癌研究（FLAGS）的次级终点结果。
2. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II) [J] . Nishikawa Kazuhiro, Tsuburaya Akira, Yoshikawa Takaki, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：Capecitabine Plus顺铂的随机期II试验与S-1加顺铂作为晚期胃癌的一线治疗：Capecitabine Plus顺铂确定与S-1加上顺铂随机化PII试验（XParts II）
3. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II) [J] . Nishikawa Kazuhiro, Tsuburaya Akira, Yoshikawa Takaki, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：Capecitabine Plus顺铂的随机期II试验与S-1加顺铂作为晚期胃癌的一线治疗：Capecitabine Plus顺铂确定与S-1加上顺铂随机化PII试验（XParts II）
4. A Successfully Treated Case of Stage IV Gastric Cancer with Outlet Stenosis Undergoing Curative Gastrectomy After Preoperative S-1 Plus Cisplatin Following Laparoscopic Assisted Gastrectomy. [C] . Y.Okumura, Y.Iwasaki, M.Ohashi, International Gastric Cancer Congress . 2009

机译：腹腔镜辅助胃切除术后，在术前S-1加顺铂术后成功处理了阶段IV胃癌的阶段胃癌。
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel cisplatin 5-FU (TCF) with epirubicin cisplatin 5-FU (ECF) [O] . Sanambar Sadighi, Mohammad Ali Mohagheghi, Ali Montazeri, 2006

机译：晚期胃癌患者的生活质量：比较多西他赛顺铂5-FU（TCF）与表柔比星顺铂5-FU（ECF）的随机试验
7. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF) [O] . 2006

机译：晚期胃癌患者的生活质量：比较多西他赛，顺铂，5-FU（TCF）与表柔比星，顺铂，5-FU（ECF）的随机试验

Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)

摘要

著录项

相似文献

相关主题

期刊订阅